Tags

Type your tag names separated by a space and hit enter

Improved Aerosolization Stability of Inhalable Tobramycin Powder Formulation by Co-Spray Drying with Colistin.
Pharm Res. 2022 Nov; 39(11):2781-2799.PR

Abstract

PURPOSE

Tobramycin shows synergistic antibacterial activity with colistin and can reduce the toxic effects of colistin. The purpose of this study is to prepare pulmonary powder formulations containing both colistin and tobramycin and to assess their in vitro aerosol performance and storage stability.

METHODS

The dry powder formulations were manufactured using a lab-scale spray dryer. In vitro aerosol performance was measured using a Next Generation Impactor. The storage stability of the dry powder formulations was measured at 22°C and two relative humidity levels - 20 and 55%. Colistin composition on the particle surface was measured using X-ray photoelectron spectroscopy.

RESULTS

Two combination formulations, with 1:1 and 1:5 molar ratios of colistin and tobramycin, showed fine particle fractions (FPF) of 85%, which was significantly higher than that of the spray dried tobramycin (45%). FPF of the tobramycin formulation increased significantly when stored for four weeks at both 20% and 55% RH. In contrast, FPF values of both combination formulations and spray dried colistin remained stable at both humidity levels. Particle surface of each combination was significantly enriched in colistin molecules; 1:5 combination showed 77% by wt. colistin.

CONCLUSIONS

The superior aerosol performance and aerosolization stability of 1:1 and 1:5 combination formulations of colistin and tobramycin could be attributed to enrichment of colistin on the co-spray dried particle surface. The observed powder properties may be the result of a surfactant-like assembly of these colistin molecules during spray drying, thus forming a hydrophobic particle surface.

Authors+Show Affiliations

Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN, 47907, USA.Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN, 47907, USA.Birck Nanotechnology Center, Purdue University, 1205 West State Street, West Lafayette, IN, 47907, USA.Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN, 47907, USA.Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN, 47907, USA.Infection Program, Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, 3800, Australia.Infection Program, Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, 3800, Australia.Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN, 47907, USA. tonyzhou@purdue.edu.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

35915320

Citation

Pathak, Vaibhav, et al. "Improved Aerosolization Stability of Inhalable Tobramycin Powder Formulation By Co-Spray Drying With Colistin." Pharmaceutical Research, vol. 39, no. 11, 2022, pp. 2781-2799.
Pathak V, Park H, Zemlyanov D, et al. Improved Aerosolization Stability of Inhalable Tobramycin Powder Formulation by Co-Spray Drying with Colistin. Pharm Res. 2022;39(11):2781-2799.
Pathak, V., Park, H., Zemlyanov, D., Bhujbal, S. V., Ahmed, M. U., Azad, M. A. K., Li, J., & Zhou, Q. T. (2022). Improved Aerosolization Stability of Inhalable Tobramycin Powder Formulation by Co-Spray Drying with Colistin. Pharmaceutical Research, 39(11), 2781-2799. https://doi.org/10.1007/s11095-022-03344-5
Pathak V, et al. Improved Aerosolization Stability of Inhalable Tobramycin Powder Formulation By Co-Spray Drying With Colistin. Pharm Res. 2022;39(11):2781-2799. PubMed PMID: 35915320.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Improved Aerosolization Stability of Inhalable Tobramycin Powder Formulation by Co-Spray Drying with Colistin. AU - Pathak,Vaibhav, AU - Park,Heejun, AU - Zemlyanov,Dmitry, AU - Bhujbal,Sonal V, AU - Ahmed,Maizbha Uddin, AU - Azad,Mohammad A K, AU - Li,Jian, AU - Zhou,Qi Tony, Y1 - 2022/08/02/ PY - 2022/02/28/received PY - 2022/07/13/accepted PY - 2023/11/01/pmc-release PY - 2022/8/2/pubmed PY - 2022/11/8/medline PY - 2022/8/1/entrez KW - combination antibiotics KW - dry powder inhalation KW - respiratory infections KW - storage stability SP - 2781 EP - 2799 JF - Pharmaceutical research JO - Pharm Res VL - 39 IS - 11 N2 - PURPOSE: Tobramycin shows synergistic antibacterial activity with colistin and can reduce the toxic effects of colistin. The purpose of this study is to prepare pulmonary powder formulations containing both colistin and tobramycin and to assess their in vitro aerosol performance and storage stability. METHODS: The dry powder formulations were manufactured using a lab-scale spray dryer. In vitro aerosol performance was measured using a Next Generation Impactor. The storage stability of the dry powder formulations was measured at 22°C and two relative humidity levels - 20 and 55%. Colistin composition on the particle surface was measured using X-ray photoelectron spectroscopy. RESULTS: Two combination formulations, with 1:1 and 1:5 molar ratios of colistin and tobramycin, showed fine particle fractions (FPF) of 85%, which was significantly higher than that of the spray dried tobramycin (45%). FPF of the tobramycin formulation increased significantly when stored for four weeks at both 20% and 55% RH. In contrast, FPF values of both combination formulations and spray dried colistin remained stable at both humidity levels. Particle surface of each combination was significantly enriched in colistin molecules; 1:5 combination showed 77% by wt. colistin. CONCLUSIONS: The superior aerosol performance and aerosolization stability of 1:1 and 1:5 combination formulations of colistin and tobramycin could be attributed to enrichment of colistin on the co-spray dried particle surface. The observed powder properties may be the result of a surfactant-like assembly of these colistin molecules during spray drying, thus forming a hydrophobic particle surface. SN - 1573-904X UR - https://www.unboundmedicine.com/medline/citation/35915320/Improved_Aerosolization_Stability_of_Inhalable_Tobramycin_Powder_Formulation_by_Co_Spray_Drying_with_Colistin_ DB - PRIME DP - Unbound Medicine ER -